Copeland Capital Management LLC Has $17.05 Million Stock Holdings in Cencora, Inc. $COR

Copeland Capital Management LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,488 shares of the company’s stock after selling 2,254 shares during the period. Copeland Capital Management LLC’s holdings in Cencora were worth $17,053,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of COR. IAG Wealth Partners LLC purchased a new position in Cencora in the third quarter valued at about $30,000. Cloud Capital Management LLC purchased a new stake in shares of Cencora during the 3rd quarter worth about $31,000. Caitlin John LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at about $31,000. Optima Capital LLC acquired a new stake in shares of Cencora during the 4th quarter valued at about $31,000. Finally, Westside Investment Management Inc. grew its stake in shares of Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after buying an additional 70 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Up 1.0%

Cencora stock opened at $311.29 on Friday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. Cencora, Inc. has a fifty-two week low of $271.00 and a fifty-two week high of $377.54. The firm has a fifty day moving average price of $338.39 and a two-hundred day moving average price of $343.01. The firm has a market cap of $60.56 billion, a price-to-earnings ratio of 37.42, a P/E/G ratio of 1.44 and a beta of 0.72.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the company posted $3.73 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, analysts forecast that Cencora, Inc. will post 17.57 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wells Fargo & Company raised their price objective on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Barclays lifted their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Robert W. Baird set a $415.00 target price on Cencora in a report on Tuesday, January 13th. Twelve analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $398.17.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.